Quality of Life and Diagnostic Considerations for FCS

Author(s):

Kausik K. Ray, MD, MRCP: From the Department of Public Health,Gerald Watts, MD, PhD

Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.

EP: 1.Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications

Now Viewing

EP: 2.Quality of Life and Diagnostic Considerations for FCS

EP: 3.PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis

EP: 4.Emerging Research of RNAi-Based Therapies for FCS

EP: 5.Reflections on Plozasiran Trial Data and Future Potential

EP: 6.SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

EP: 7.Novel Research Frontiers on the Management of FCS

Video content above is prompted by the following:

What economic burden does familial chylomicronemia syndrome have on patients?